Clinical trial · Interventional
Ixabepilone Administered as an Enteric Coated Formulation.
An Exploratory Study of Ixabepilone Administered as an Enteric Coated Formulation in Patients With Advanced Cancer.
NCT00309049CI-TRIAL-00025704completedPhase 1 / Phase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to determine the pharmacokinetics of oral Ixabepilone.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Ixabepilone | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- ACTIVE_COMPARATOR
- label
- A1
- interventionNames
- Drug: Ixabepilone
- type
- ACTIVE_COMPARATOR
- label
- A2
- interventionNames
- Drug: Ixabepilone
- type
- ACTIVE_COMPARATOR
- label
- A3
- interventionNames
- Drug: Ixabepilone
Primary outcomes (1)
- measure
- Determine the action of Ixabepilone in the body over a period of time including the process of absorption, distribution, metabolism and elimination.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * ECOG status of 0-2. Exclusion Criteria: * Unable to swallow pills. * Current or recent GI disease or GI surgery. * Brain mets. * Severe nerve damage. * ANC \<1,500/mm3 * Platelets \<125K. * Bilirubin \>=1.5 times the IULN. * ALT/AST \>=1.5 times the IULN. * Creatine \>1.5 times the IULN. * Prior treatment with Ixabepilone. * Strong use of CYPP450 drugs.
References
Publications (0)
Data not yet available
No reference posted for this study.